Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Y-2 Sublingual Tablet in Healthy Adults
NCT05940883Phase 1Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of edaravone and dexborneol in ischemic stroke (6 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Adverse Events, Maximum concentration at Day 12 and 3 more. Started Sep 2023; status: completed.
02
Drugs
edaravonedexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05940883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940883.